These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34337142)

  • 21. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 23. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
    Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect.
    Wen X; Shi C; Zeng X; Zhao L; Yao L; Liu Z; Feng L; Zhang D; Huang J; Li Y; Lin Q; Chen H; Zhuang R; Chen X; Zhang X; Guo Z
    Clin Cancer Res; 2022 Jul; 28(13):2923-2937. PubMed ID: 35320358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of exosomal PD-L1 in tumor progression and immunotherapy.
    Xie F; Xu M; Lu J; Mao L; Wang S
    Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
    Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
    Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8
    Chen J; Song Y; Miao F; Chen G; Zhu Y; Wu N; Pang L; Chen Z; Chen X
    Cancer Sci; 2021 Sep; 112(9):3437-3454. PubMed ID: 34152672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.
    Yang J; Chen J; Liang H; Yu Y
    Cancer Sci; 2022 Sep; 113(9):3044-3054. PubMed ID: 35598173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer.
    Shen DD; Pang JR; Bi YP; Zhao LF; Li YR; Zhao LJ; Gao Y; Wang B; Wang N; Wei L; Guo H; Liu HM; Zheng YC
    Mol Cancer; 2022 Mar; 21(1):75. PubMed ID: 35296335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
    Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
    J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Detection of Exosomal PD-L1 in Peripheral Blood.
    Wang R; Yang Y; Huang J; Yao Y
    Methods Mol Biol; 2023; 2695():195-212. PubMed ID: 37450120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
    Kim DH; Kim H; Choi YJ; Kim SY; Lee JE; Sung KJ; Sung YH; Pack CG; Jung MK; Han B; Kim K; Kim WS; Nam SJ; Choi CM; Yun M; Lee JC; Rho JK
    Exp Mol Med; 2019 Aug; 51(8):1-13. PubMed ID: 31399559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation.
    Reyes RM; Zhang C; Deng Y; Ji N; Mukherjee N; Padron AS; Clark CA; Svatek RS; Curiel TJ
    Oncoimmunology; 2021; 10(1):2006529. PubMed ID: 34858732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
    Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.
    Cordonnier M; Nardin C; Chanteloup G; Derangere V; Algros MP; Arnould L; Garrido C; Aubin F; Gobbo J
    J Extracell Vesicles; 2020; 9(1):1710899. PubMed ID: 32002173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorescence Super-Resolution Imaging Chip for Gene Silencing Exosomes.
    Yin G; Qi T; Wei J; Wang T; Wang Z; Cui Y; Zong S
    Sensors (Basel); 2023 Dec; 24(1):. PubMed ID: 38203034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel insights into the regulation of exosomal PD-L1 in cancer: From generation to clinical application.
    Liu J; Qin J; Liang L; Zhang X; Gao J; Hao Y; Zhao P
    Eur J Pharmacol; 2024 Sep; 979():176831. PubMed ID: 39047964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody.
    Lee EJ; Jang GY; Lee SE; Lee JW; Han HD; Park YM; Kang TH
    Immunol Lett; 2021 Dec; 240():137-148. PubMed ID: 34710507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.